Vera Therapeutics (VERA) Long-Term Deferred Tax (2023 - 2026)
Vera Therapeutics' (VERA) quarterly Long-Term Deferred Tax came in at $2.0 million in Q1 2026, down 18.08% on a QoQ basis from $2.5 million in Q4 2025.
Vera Therapeutics (VERA) Long-Term Deferred Tax (2023 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 3 years of Long-Term Deferred Tax data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Long-Term Deferred Tax changed N/A year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $2.5 million, changed N/A from the prior year.
- Long-Term Deferred Tax declined to $2.0 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $2.5 million in Q4 2025 to a low of $719000.0 in Q4 2023.
- A 3-year average of $1.7 million and a median of $2.0 million in 2026 frame the typical range for Long-Term Deferred Tax.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.03 Mn |
| Dec 31, 2025 | 2.47 Mn |
| Dec 31, 2023 | 719,000.00 |